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ABSTRACT
Purpose We examine the levels of post- trial 
responsibility ascribed to different stakeholders, 
following a community- based clinical trial and how the 
’responsibility’ is understood.
Methods We employed photovoice, unstructured 
observations and key informant interviews to gain 
insights into contexts of access to care following 
transition to the public health system post trial. We used 
an inductive narrative analysis to explore experiences 
and understandings of post- trial access (PTA).
Results In their photovoice stories, many participants 
expressed a sense of abandonment after the trial. 
This was viewed as a contributing factor to failing 
to re- engage with care available in the public health 
system. This led to the experiences of loss as some trial 
participants defaulted and died. Research investigators, 
department of health participants and sponsor agreed 
that PTA was especially important for communities 
in resource- limited settings. The government has an 
obligation towards its citizens while researchers have a 
responsibility to ensure a smooth transition of patients 
to public clinics. Sponsors have a responsibility to 
ensure that the trial is conducted in accordance with 
the protocol and post- trial agreements are in place and 
adhered to. Research partnerships among stakeholders 
were affected by power imbalances making it difficult to 
negotiate and plan for post- trial care responsibilities.
Conclusions The research community still struggles 
with understanding the scope of PTA responsibilities. 
Power dynamics between public health actors and 
research sponsors need to be managed to ensure 
that government involvement is not tokenistic. The 
responsibility of trial participants and ethics committees 
needs to be investigated further.
BACKGROUND
In 2000, post- trial access (PTA) was included in the 
Declaration of Helsinki as an issue of concern for 
researchers, recognising the need to protect trial 
participants beyond their participation in clinical 
research. In October 2013, the World Medical 
Association approved a version of the Declaration 
of Helsinki which for the first time in the 49 years 
of its existence requests governments to take 
responsibility for research participants and their 
communities.1 There is still much debate within the 
research community on the meaning and interpre-
tation of the amendment. This 2013 Declaration of 
Helsinki amendment states that, ‘at the conclusion 
of a study, patients should be assured of access to 
the best proven prophylactic, diagnostic and ther-
apeutic methods identified by the study’; the 2006 
Universal Declaration on Bioethics and Human 
Rights goes further suggesting that PTA should be 
more than just the availability of the investigated 
medicine.2 The United States National Bioethics 
Advisory Committee recommends that sponsors 
and researchers make good faith efforts in ensuring 
continued access to experimental interventions that 
have been proven effective for the participants.3 
Yet, these statements do not offer guidance on how 
this can and should be done.4–6
Focusing on an investigational drug or interven-
tion for PTA omits the equally important aspects 
of the care of a participant that goes beyond the 
drug.7 8 Other responsibilities for post- trial care 
include arranging the transition to other clinical 
care, ensuring existence of appropriate follow- up 
and arranging social support services to ensure a 
smooth transition to arranged clinical care.9 10
Ethical responsibilities of researchers, sponsors 
and even the government that are concerned with 
the health and safety of participants are usually laid 
out clearly during the trial and yet these abruptly 
come to an end with trial completion.9 11 This is 
of critical importance in many low- income and 
middle- income countries where participants may 
not have access to affordable healthcare systems 
leading to potential exploitation of vulnerable 
communities.4 8 10 The challenges associated with 
PTA of drugs or care comprise of issues including 
distributive justice, potential for exploitation and 
the argument to treat participants with human 
dignity.12 13
In this article, we examine how the meaning of 
responsibility is understood and levels ascribed to 
different stakeholders in a study using a Universal 
Test and Treat (UTT) HIV trial as a case study.14
METHODS
We integrated photovoice, unstructured observa-
tions and semistructured interviews. We began by 
identifying PTA principles in international legisla-
tion and guidelines and reviewed current academic 
literature to develop the topic guide. Photovoice is 
a visual participatory approach that involves partic-
ipants taking photos to help them document and 
narrate their story around certain issues of concern 
while promoting critical dialogue. It was appro-
priate for this study as we sought to empower indi-
viduals to ‘voice’ their individual perceptions and 
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experiences of PTA to treatment and any impact on their lives 
and photovoice engages with participants from marginalised 
communities in identifying issues that affect them from their 
own point of view.15
Study setting
This study was undertaken in the rural Hlabisa subdistrict of 
uMkhanyakude district, KwaZulu- Natal province, South Africa. 
uMkhanyakude is one of the poorest districts in South Africa; 
only about 22% of the population have access to piped water 
and sanitation.16 The area is characterised by dispersed rural 
settlements with most households depending on small- scale agri-
culture and government grants. Outmigration to urban centres 
for work is quite common. Despite the large scale up of HIV 
care and treatment in South Africa, the area still experiences the 
highest HIV incidence among adolescent girls and women and 
has a high HIV burden.16 17
Description of case study
This research is based on a case study of a UTT trial that used 
antiretroviral treatment (ART) as a prevention method to 
decrease the risk of HIV transmission implemented in purpose- 
built trial clinics from 2012 to 2016. The main eligibility 
was that the individual was HIV- positive. The trial provided 
comprehensive care for HIV- positive individuals including care 
for common medical conditions or any intercurrent illness not 
requiring hospital admission. The primary outcome of the trial 
was a measure of HIV incidence, using longitudinal dried blood 
spots from participants every 6 months. Prior to trial comple-
tion, other evidence from NIH- sponsored START trial and the 
ANRS- sponsored TEMPRANO trial reported that early ART 
initiation has significantly greater health benefit to HIV- positive 
people.18 19 Given this effectiveness of ART initiation outside 
standard practice, consideration of PTA would be essential for 
patients’ well- being. Another concern for PTA in this study was 
the provision of 22 new study clinics located close to people’s 
homes in an area with only three public clinics. During the 
informed consent process and at various intervals during the 
trial, participants were informed that after the completion of 
the trial or if they decided to withdraw, they would be trans-
ferred to the local department of health clinics’ treatment and 
care programme where they would continue to receive HIV care 
and treatment. During the last year of the trial, participants were 
informed of the transition procedure and that their records will 
be transferred to their preferred government clinic.
Current study
Photovoice was used as a visual participatory method to engage 
with participants in a series of training and discussion work-
shops. These three workshops took place over 8 days (figure 1), 
facilitated by NP, an expert in community engagement using 
participatory methods. A convenience sample of participants 
that had been involved in the UTT trial and their families was 
identified through the Africa Health Research Institute database 
and invited according to the following categories: (1) families 
with a member who is still adhering to treatment at the clinic, (2) 
families with a member who is no longer adhering to treatment 
at the clinic and (3) families with a member who is deceased. 
Recruitment for this study took place over 2 weeks in January 
2019. Overall, 10 out of 12 people invited (3 male, 7 female) 
enrolled in the photovoice project.
The inception workshop took place over 3 days where partic-
ipants had comprehensive training on the methods, on using the 
cameras and ethics of photovoice. They had the opportunity 
to take pictures and receive guidance. They then had 1 month 
to capture images within their community that illustrated their 
perception of life before the trial, life during the trial and life 
after the trial. They were given notebooks with specific prompts: 
(1) Who or what is in the photo? (2) When did you take it? (3) 
Why did you take the picture? and (4) How does it make you 
feel? This was later used by the participants to construct their 
narratives and contextualisation for each specific photograph. 
All photographs were developed and printed in colour during 
the next workshop which lasted 4 days. During this workshop, 
participants reviewed their pictures and shared as a group why 
they took the picture. We applied narrative analysis techniques to 
explore the photographs and frame its accompanying narration 
and stories, as led by the participants.20 21 The participants led 
the categorisation and thematic grouping of photos and discus-
sions. Some people asked for more time to take more pictures as 
they felt that they had not followed the brief. This was followed 
by the final review and reflection day where they discussed 
their photographs and the researchers assisted by typing out the 
narration/caption of each photograph. The same methodolog-
ical process using narrative analysis techniques was applied to 
these photos. These were displayed on a wall and participants 
then organised the photos thematically and by prioritisation. On 
this last day, participants were invited to sign a release form for 
their photos and videos taken. Permission for reuse of photos 
was obtained from all participants. Participant identifiers are 
not used for photos or quotations to protect the privacy of the 
research participants.
Semistructured interviews were conducted with principal 
investigators (PIs) of the trial, members of the subdistrict, district 
and provincial level Department of Health (DoH) and a sponsor 
between October 2019 and February 2020. Purposive sampling 
was employed with an invitation sent to the PIs and members 
of DoH who were aware of and at some point, involved in the 
trial. The goal of the interviews with PIs, DoH and sponsor was 
to explore the pretrial agreements, what happened after the 
trial, whether this was in line with PTA guidelines and protocol 
and ideally what the different responsibilities of each of these 
stakeholders should be. All the interviews were conducted by the 
first author (NN) working with two of the coauthors (SN and 
UN) who facilitated data collection and another coauthor who 
is a public engagement officer (NM). Preliminary analysis was 
conducted manually by three of the authors using open coding, 
guided by the study research focus but also following a grounded 
theory approach to capture new themes emerging from the data. 
Following manual coding, the data were uploaded and recoded 
using N- Vivo V.12 software and analysed thematically. Emerging 
themes were discussed and compared across the dataset. The 
recurrent pattern of these new themes gave confidence that key 
areas had not been omitted from the dataset.
RESULTS
We present the visual narratives from the photovoice part 
of the study as well as extracts from the in- depth interviews Figure 1 Photovoice research process.
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regarding perceptions of PTA responsibilities and community 
needs. Two interviews were conducted by telephone and four 
were conducted face to face. Community needs (lack of care 
access, tradition and support, loss and desertion) is one of the 
major themes abstracted from the participant- participatory anal-
ysis while the researchers and DoH professionals focused on 
expressing their understanding of the different responsibilities 
that all stakeholders should have. The visual narratives aim to 
demonstrate the community’s views on the impact of the trial as 
well as the ending of the trial in relation to access to care.
Participants took over 120 photographs during the entire 
project which were then categorised into 8 categories. These 
categories were further organised around three themes: (1) lack 
of access, (2) tradition and support and (3) loss and desertion.
Lack of access
Participants expressed how access to healthcare services was 
quite problematic and they had to either walk a long distance to 
get to their clinics for access to treatment or find other means of 
transport which is not easily available to everyone as illustrated 
in figure 2A,B. The concept of removing the trial facilities that 
offered ARTs close to their homes was a topic of discussion and 
participants felt that they were neglected by the research insti-
tute. They emphasised how the trial clinics close to their homes 
was part of the intervention as much as the ARTs were.
Tradition and support
Throughout the project, narratives were shared that showed 
the impact of post- trial care as portrayed in figure 3A,B. All the 
participants shared how the community members recognised the 
significance of the end of the trial as well as observed the impact 
of this through people resorting to traditional medicines and 
defaulting from treatment.
Loss and desertion
The perception of the trial being linked to loss permeated some of 
the narratives which highlighted the emotional responses to the 
death of loved ones and other villagers as shown in figure 4A,B. 
Participants also shared how the deserted clinical trial facilities 
were a constant reminder of life post trial and emphasised the 
need for AHRI to reinstate this trial which many viewed as a 
service rather than research.
Roles and responsibilities from interview participants
Legal obligation to provide PTA for the government
Participants shared their perspectives of the different respon-
sibilities that stakeholders had and to whom they had that 
responsibility. Responsibilities were described as giving access to 
treatment and sometimes as taking care of participants as one PI 
said, ‘what had been agreed prior to the trial starting, …was that 
the Department of Health had agreed to make treatment avail-
able to all participants at the end of the trial’. This responsibility 
was also shared by individuals from the department of health as 
one participant said, ‘So, it should be the Department of Health 
that would eventually take over’. Sentiments were however 
shared on the financial challenges for the government due to 
limited resources, ‘Department has to look at the numbers of 
patients on treatment and then develop the way forward like 
we’d have to see whether we would be able to cater if we had 
enough budget’. One DoH interviewee shared sentiments on 
power dynamics between researchers and the government that 
could potentially lead to pressurised agreement of PTA as the 
government needs to look after its people, ‘In most trials there 
is always a delay because DoH has not signed because DoH 
is concerned about this and that and that and that. However, 
the pressure, you know academic people have…So most of the 
time, DoH tries to look after the interest of the public. But the 
odds are usually against DoH. Somebody ends up signing under 
pressure’.
Responsibility of awareness of PTA for sponsors
There were mixed views when it came to the responsibility 
of the sponsors. Two investigators’ perspectives were that the 
sponsor did not have a direct responsibility for PTA. Research 
staff expressed that the sponsor had ‘a responsibility or an 
awareness (of PTA) and that they should also you know, be 
receptive to further applications, I guess, for support relating to 
questions that come out of the trial that they have sponsored. I 
do not think that the sponsors have got a direct responsibility for 
Figure 2 (A,B) Lack of access.
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post- trial access’. The sponsor interviewee however shared that 
the sponsor had a legal responsibility that any agreements docu-
mented in a protocol are carried out and expressed that ‘My 
view is that the sponsor is responsible for all aspects that the trial 
should take place under perfect conditions according to all the 
rules that exist…and that includes the post- trial provision’. This 
person referred us to the sponsor’s ethics charter for research 
in developing countries which states that part of their require-
ment from investigators when applying for funds is to ‘define 
postresearch support conditions’ and to discuss the provision of 
equivalent interventions if effective treatment/interventions are 
not available at the end of the project.
One DoH participant seemed to think that sponsors had a 
bigger responsibility than shared by others and contrasted policy 
or legal responsibilities of the sponsor to the mining industry 
where mines have a legal responsibility to rehabilitate the envi-
ronment after mining. Research is a ‘data mining operation’ and 
should have a policy that requires a form of rehabilitation of 
communities and the sponsor should have a financial respon-
sibility for rehabilitation. They went on to explain that better 
provision of PTA and/or responsible transition of research 
participants is needed to ensure that they are not left in a worse 
condition than they were before the trial.
Figure 3 (A,B) Tradition and support.
Figure 4 (A,B) Roles and responsibility.
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Social responsibility by investigators
There seemed to be general agreement from the three PIs that 
they had some responsibility to ensure benefit to the community 
and to avoid harm to participants, ‘I think the responsibility is 
to ensure that trial participants or those willing to enter a trial 
on behalf of research, benefit themselves and that based on the 
outcome of the trial, of the study, that the broader community 
benefits from that’. Investigators shared how their responsibility 
was mostly to ensure no harm came to the participant during the 
trial and part of that was to support the transition to the public 
HIV treatment programme, as one said, ‘it is not the responsi-
bility of the scientists to organize the HIV treatment program 
thereafter, but it is the responsibility of the science to make sure 
that that could happen by national program and to support that’.
Two other stakeholders who had not been considered prior 
the study were raised by the interviewees; the ethics committee 
and its responsibility to monitor how investigators consider PTA 
in the protocol and the participants themselves as one inter-
viewee said, ‘responsibility lies with the individual who partic-
ipated voluntarily in the study’, as they would have been given 
all the information including what would happen at the end of 
the trial before the trial commenced. PIs however felt that this 
was a challenge as one said, ‘there’s a very poor understanding of 
research, internationally there’s a poor understanding of research 
by research participants within (research Institute) research 
participants’ and therefore this would make it difficult to place 
responsibility with the community members. One researcher 
echoed and offered an explanation for the poor understanding 
and expressed that the nature of the trial was ‘less of a clinical 
trial and more as part of a service delivery so I can understand 
that’s what the community sees as well,… it was a clinical trial 
but it was more of an implementation trial’ which also had its 
own implications as the institute functioned as a service provider 
which was providing specialised care to individuals.
DISCUSSION
Similar to previous studies, our findings reveal the extent of the 
impact of PTA including concerns of abandonment and potential 
for defaulting treatment.4 8 The practicalities are quite challenging 
and not as easy to implement as stakeholders involved cannot indi-
vidually guarantee PTA due to many other considerations such as 
costs and feasibility.1 5 7 The UTT trial participants shared feelings 
of abandonment after the trial closure leading to their reliance on 
traditional medicine and culture for support. One explanation of 
this could be the lack of understanding of research compared with 
healthcare service provision with participants seeing the trial as a 
service to them that would not come to an end.
The study illustrated how factors ascribed to responsibility 
are inter- related with challenges in conceptualisation and under-
standing of responsibility sometimes leading to major flaws in 
practice. Most researchers perceive that the government has a 
legal obligation as the National Department of Health to fulfil 
its mission to improve the health and healthcare delivery systems 
for its citizens. This finding supports the DoH amendment to 
include governments as a stakeholder that has a responsi-
bility for PTA to ensure continued access to treatment for its 
people.22 23 However, the power dynamics expressed by the DoH 
interviewees have implications on the trial agreements drawn at 
the beginning of the trial. Therefore, mechanisms are needed to 
mitigate differentials in power if these trial agreements are to be 
used as instruments to implement PTA obligations.
In normative discussions, the investigators have a social respon-
sibility as ‘scientists’ which often is driven by the usefulness of the 
research outcomes and addressing relevant health problems.24 25 
Social responsibility is not about an individual investigator, but 
is an ethical aspect that is operational within an organisation 
and governs its conduct.26 Socially responsible and responsive 
health research practices focus on doing no harm which would 
involve responsible transitioning of participants to the standard 
of healthcare they need so as to leave people no worse off than 
before the trial.9 On the other hand, the sponsor has a legal 
responsibility according to Good Clinical Practice guidelines to 
ensure and monitor that the trial is conducted according to the 
protocol including ensuring that any post- trial agreements are in 
place and adhered to. What remains unanswered by this study is 
what is considered a reasonable execution of this responsibility 
from the various stakeholders.
An interesting finding is the question raised on the responsibil-
ities of ethics committees and trial participants. Further research 
is needed to explore the responsibilities of these stakeholders as 
raised in this study.
Our exploratory analysis is subject to certain limitations 
including the modest sample size due to our access to partici-
pants and as such the conclusions are not definitive. There is 
great potential for recall bias due to the duration between the 
end of the case study trial and the current study. Generalisation 
of the findings to other study trial may be limited, because in 
the case study trial, the drugs were freely available in the public 
ART programme, however the study highlights that aspects of 
‘care’ extend beyond a narrow conception of access where the 
availability of a drug free of cost was not a barrier, as participants 
expressed negative experiences because of the end of the trial. 
The triangulation of data collected add value to the project and 
photovoice empowered participants to decide the narrative of 
importance to them on their PTA experiences and concerns held. 
Future research could include an exploration of these post- trial 
aspects in the other UTT trial sites for comparability and cross- 
fertilisation lessons.
CONCLUSION
The issue of PTA to treatment is an ethical dilemma that is still 
debated and the research community struggles with under-
standing the scope and extent of responsibilities. Implications 
of the implementation of PTA guidelines is challenging due 
to these differing views and understanding of responsibilities 
among different stakeholders, and this study shows how some 
participants are bearing the burden of this uncertainty. This 
small exploratory study highlights voices of participants in their 
experience of lack of access, loss of support and desertion. It 
further identifies an additional implementation challenge of 
power dynamics between public health actors and research spon-
sors, suggesting that there is a significant gap between ensuring 
continued availability of trial treatments and maintaining a sense 
of care for the participants.
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